Europe PMC

Objective This study aims to evaluate the clinical impacts of topical and/or oral administration of compounds rich in omega-3 fatty acids from various sources, such as oils and foods, on psoriatic lesions.Design A systematic review was carried out.Data sources Searches were conducted in six databases (PubMed, Cochrane, VHL, Scopus, Embase, and Web of Science) using descriptors related to fatty acids and psoriasis.Study selection Inclusion criteria were studies published in the last 10 years (201

Background Psoriasis is an erythema papulosquamous dermatosis that cannot be cured at present. Pithecellobium clypearia Benth. belonging to the Leguminosae family and is clinically used as a treatment for gastroenteritis, acute tonsillitis, acute pharyngitis, and upper respiratory tract infections. Our previous studies have found that P. clypearia can improve imiquimod (IMQ)-induced psoriasis in mice and have revealed some differential metabolites and pathways using metabolomics methods. However

Psoriasis is a chronic immune-mediated disease mainly affecting the skin with different clinical manifestations. As patients with psoriasis may also suffer from psoriatic arthritis and the skin lesions of psoriasis are disfiguring, their quality of life is often impaired. Many environmental and genetic factors have been implicated in psoriasis development. Currently, there is no cure for the disease and long-term drug treatment is usually necessary, especially in moderate to severe cases. Mesenc

Importance Patient-reported outcome (PRO) assessments alongside clinical parameters help to holistically determine treatment benefits.Objective To assess PROs among bimekizumab-treated patients with moderate to severe plaque psoriasis.Design, setting, and participants The BE RADIANT multicenter, phase 3b randomized clinical trial and open-label extension (OLE) had a 48-week double-blinded period and 96-week OLE (3 years' total treatment). Patients initially received bimekizumab or secukinumab. A

Background Psoriasis is frequently associated with metabolic syndrome and an increased cardiovascular risk. Tildrakizumab, an IL-23 inhibitor, may affect metabolic parameters in addition to improving skin severity.Aim of the study To evaluate the impact of increasing tildrakizumab dosage on lipid and glucose levels in psoriasis patients with metabolic syndrome who showed a partial response to the standard 100 mg dose.Materials and methods Twenty-five patients with psoriasis and metabolic syndrom

Objective To assess the real-world efficacy and safety of tildrakizumab in Chinese patients with psoriasis stratified by age, age of psoriasis onset and MetS status.Methods This two-center retrospective cohort study evaluated tildrakizumab's efficacy and safety over 28 weeks in 80 Chinese adults with moderate-to-severe plaque psoriasis, with subgroup analyses by age and age of psoriasis onset and metabolic syndrome (MetS).Results Mean PASI scores showed progressive improvement, declining from 9.

Objectives Conflicting data exist on TNF inhibitors' (TNFi) role in preventing psoriatic arthritis (PsA) in psoriasis. Using propensity score matching, we compared PsA incidence in severe psoriasis patients treated with TNFi versus narrow-band ultraviolet B (nbUVB) phototherapy over a decade of follow up.Methods Consecutive adults with severe psoriasis prescribed TNFi or nbUVB phototherapy between September 2005 and September 2010 were enrolled. Of 946 patients, 497 received TNFi (median follow-

Psoriasis is a chronic skin disease mediated by Th1 and Th17 immune responses and is classified as a systemic inflammatory disorder. Notably, psoriasis is an independent risk factor for myocardial infarction, stroke, and cardiovascular mortality, particularly in severe disease. However, the cellular mechanisms linking psoriasis to cardiovascular disease have not yet been identified. To address this gap, we investigated systemic markers of inflammasome signaling and innate immune activation in pa

ABSTRACT Background Psoriasis is a chronic skin disease mediated by Th1 and Th17 immune responses and is classified as a systemic inflammatory disorder. Notably, psoriasis is an independent risk factor for myocardial infarction, stroke, and cardiovascular mortality, particularly in severe disease. However, the cellular mechanisms linking psoriasis to cardiovascular disease risk have not yet been identified. To address this gap, we investigated systemic markers of inflammasome signaling and i

Purpose To explore the mechanism of cuprotosis in psoriasis, screen cuprotosis related genes (PDCRGs) in psoriasis, and provide new targets for precise diagnosis and treatment of psoriasis.Material and methods Integrate bioinformatics analysis and experimental validation. Firstly, based on the GEO database (GSE161683, GSE166388, GSE277173), differentially expressed genes (DEGs) and weighted gene co-expression network analysis (WGCNA) in psoriasis were screened; Identification of differential cup

Objectives To determine which anatomical sites and which ultrasonographic entheseal lesions are best able to discriminate between spondyloarthritis (SpA) patients and healthy controls (HC).Methods We included patients with psoriatic arthritis (PsA) and axial SpA (axSpA), from six Swiss hospital outpatient clinics, as well as HC. Participants completed quality of life and physical activity questionnaires and underwent a clinical examination of both joints and entheses, followed by a detailed musc

Objectives To test the hypothesis that recently-developed total body-positron emission tomography (TB-PET) imaging with integrated computed tomography (CT) will enable low-dose, quantitative, domain-specific evaluation of the total inflammatory burden of psoriatic arthritis (PsA) and associate with established outcome measures of the clinical domains of PsA.Methods Seventy-one adult participants (40 with PsA, 16 with rheumatoid arthritis (RA), and 15 with osteoarthritis (OA)) underwent 20-min TB

Objective Psoriatic arthritis (PsA) guidelines aim to provide consistent, evidence-based recommendations. Multiple regional guidelines exist, often based on similar evidence but with different methodologies and contexts. Our aim was to compare recent PsA treatment guidelines from the American College of Rheumatology, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis, European Alliance of Associations for Rheumatology, and Pan American League of Associations for Rheumatology,

Introduction Difficult-to-treat psoriatic arthritis (D2T-PsA) is increasingly recognized as a complex clinical entity characterized by persistent disease burden despite multiple targeted therapies. Its identification is essential to improve patient outcomes and to guide the development of new therapeutic strategies.Areas covered In this perspective article, we discuss the evolving concept of D2T-PsA, including its epidemiology, clinical characterization, and underlying pathophysiological mechani

Background The clinical definition of moderate psoriasis is debated, affecting treatment eligibility and patient outcomes.Objective A panel of Italian dermatologists aimed to propose practical criteria to define moderate psoriasis, based on a comprehensive literature review and clinical experience.Methods The panel reviewed publications between 2016 and 2024 focusing on key severity scores, including the Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), Dermatology Life Quality

Context Evidence regarding the relationship between serum trace element levels and immune-mediated inflammatory skin diseases (IMSDs) is inconsistent.Objective In this systematic review and meta-analysis we aimed to evaluate the association between selected serum trace element levels (zinc [Zn], copper [Cu], iron [Fe], selenium [Se], and calcium [Ca]) and IMSDs (psoriasis, vitiligo, atopic dermatitis [AD], alopecia areata [AA], hidradenitis suppurativa, and bullous diseases).Data sources We cond

No abstract supplied.Weiterlesen

Background Despite increased understanding of psoriasis pathogenesis, molecular classification of clinical phenotypes and disease severity is poorly defined. Knowledge gaps include whether molecular endotypes of psoriasis underlie distinct clinical phenotypes and the positive and negative molecular regulators of disease severity across tissue compartments.Methods We performed comprehensive RNA sequencing of skin and blood (n = 718) from prospectively-recruited, deeply-phenotyped discovery and re

Justification and objectives: Topical therapy is vital in the management of psoriasis. In recent years there have been multiple advances and changes in the management of psoriatic patients that justify a review and update of the use of topical therapy. Experts from the Spanish Psoriasis Working Group (GPS) of the Spanish Academy of Dermatology Venereology (AEDV) have developed a set of recommendations for the treatment of psoriasis based on the best available evidence and experts' opinion. Metho

Secukinumab, a fully human monoclonal antibody that antagonizes interleukin-17A (IL-17A), has proven efficacious in the management of moderate to severe plaque psoriasis. Secukinumab has established itself as an effective treatment for plaque psoriasis, offering rapid and sustained symptom improvement. However, more research is warranted to assess its efficacy and safety in elderly patients, where clinical data is currently lacking. We describe an 84-year-old female presented with stable angina

Generalized pustular psoriasis (GPP) is a potentially life-threatening infrequent immune-mediated disease characterized by rapid-onset of erythematous plaques, sterile pustules, and systemic inflammation. Spesolimab, a monoclonal antibody targeting the interleukin-36 receptor, is a novel treatment for GPP. However, GPP's low incidence and limited evidence represents a challenge in determining its real-world efficacy. This review aims to explore the clinical use of spesolimab in a real-world sett

Keratinocyte hyperproliferation and excessive inflammatory responses are associated with psoriasis pathogenesis. Trifolirhizin has anti-inflammatory and anti-proliferation effects. The purpose of the study was to investigate the role of trifolirhizin in psoriasis-like skin lesions and its molecular mechanism. Imiquimod-induced psoriasis-like mouse models were treated with trifolirhizin. Skin lesions and inflammatory factors were assessed. In vitro, human HaCaT keratinocytes were stimulated by a

Background Genetic susceptibility to psoriasis involves multiple loci, including TYK2 (Tyrosine Kinase 2), which is associated with various autoimmune diseases. However, its specific role and mechanisms in psoriasis remain unclear. This study aimed to identify psoriasis-associated proteins using Summary-based Mendelian Randomization (SMR) and to explore their regulatory mechanisms.Methods SMR analysis integrating pQTL data was conducted to identify proteins linked to psoriasis, revealing ICAM1 (

Introduction Research findings show a substantial correlation between Crohn's disease and psoriasis. However, the exact cause or pathogenesis of the concurrent manifestations of these two conditions in the same individuals remains uncertain. This research aimed to scrutinize the important molecules and mechanisms responsible for the concomitance of Crohn's disease and Psoriasis by using quantitative bioinformatics utilizing a publicly available RNA sequencing repository.Methods The database Gene

Cumulative life course impairment (CLCI) is the irreversible harm resulting from the chronic burden of disease, such as psoriasis. This cumulative impact encompasses physical, psychological, social, and emotional challenges that can significantly alter the life trajectory of a patient with psoriasis. The risk of CLCI and the impact of living with psoriasis are exacerbated when the disease is inadequately managed. Even with improvements in skin symptoms, psychological factors, such as anxiety abo